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ABSTRACT
To reduce the toxicity of traditional conditioning regimens for allogeneic stem cell transplantation (allo-SCT),
we used single-agent chemotherapy conditioning with either busulfan (total cumulative dose, 16 mg/kg) or
melphalan (200 to 240 mg/m2), followed by the anti–T cell–specific monoclonal antibody T10B9 (MEDI-500)
daily for 3 days. T cell–replete SCT was performed from HLA-identical sibling donors. Acute graft-versus-host
disease (aGVHD) prophylaxis consisted of 7 additional days of T10B9 and delayed onset of cyclosporine (ie, on
day 4 or 5). Twenty-six high-risk hematologic malignancy patients were entered onto this study. All 24
patients who survived longer than 8 days engrafted, although 1 patient experienced late graft failure. Deaths
occurred in 21 of 26 patients because of infection (n  7), progression/recurrence of primary disease (n  6),
aGVHD (n  4), regimen-related toxicity (n  1), and other causes (n  3). Five of these patients are enjoying
disease-free survival with a median survival of 1193 days after allo-SCT. The conditioning regimen induced
modulation of surface expression of CD3 (but not CD4 or CD8) and was associated with decreasing tumor
necrosis factor- (but not interleukin-6) serum levels. In conclusion, single-agent chemotherapy conditioning
with T10B9 produced durable engraftment and long-term survival in some patients who would not have
qualified for a traditional allo-SCT.
© 2004 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
The curative beneﬁts of allogeneic stem cell trans-
lantation (allo-SCT) have been muted by the toxicity
f traditional regimens, including high-dose radiation
nd chemotherapy [1,2]: graft-versus-host disease
GVHD) [3,4], an increased incidence of severe infec-
ion [5], disease recurrence, and the risk of second
alignancies [6]. As a result, allo-SCT has usually
een restricted to younger and more ﬁt patients with
ell-matched donors and to primary transplantations.
atients who are older, who have comorbid disease, or c
58ho have received a previous transplant are at higher
isk for nonrelapse mortality [7,8]. New approaches
re needed to extend allo-SCT to these so-called
igh-risk patients.
There is now clear evidence indicating that com-
only used conditioning regimens not only cause in-
reased regimen-related toxicities (RRT), but also are
major factor in the pathogenesis of acute GVHD
aGVHD) [9-15]. Both experimental and clinical stud-
es performed by ourselves [13,14] and others
9-12,15] have established that pretransplantation
onditioning with myeloablative doses of total body
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T Cell–Specific Monoclonal Antibody in Novel Allo-SCT
Brradiation (TBI) and certain cytotoxic drugs is a ma-
or factor in the incidence and severity of aGVHD.
hese experimental and clinical studies demonstrated
hat pretransplantation TBI acts not only to reduce
he host/antigraft reaction, but also to augment the
llogeneic aGVHD response [13]. Although de-esca-
ation of the doses of TBI and/or cytotoxic drugs
ight address this issue, a reduction might also reduce
he anticancer beneﬁt. Moreover, it now seems that
he role of conditioning to ablate tumor cells may be
o more important than its role to provide sufﬁcient
mmunosuppression to allow allogeneic engraftment.
The adverse effects of aggressive conditioning are
ediated, in part, by the induction of high levels of
roinﬂammatory cytokines [9-15]. Therefore, consid-
rable emphasis has been placed in recent years on
esigning conditioning regimens that achieve immu-
osuppression while reducing RRT and the propen-
ity to induce proinﬂammatory cytokines [16-23]. We
eport herein the results of a pilot trial for high-risk
atients in which conditioning was limited to single-
gent therapy with busulfan or melphalan followed by
he pretransplantation and posttransplantation intra-
enous administration of MEDI-500, a clone of the T
ell–speciﬁc monoclonal antibody T10B9 [24,25]. To
etermine whether this protocol reduced the levels
f inﬂammatory cytokines, tumor necrosis factor
TNF)– and interleukin (IL)–6 serum levels were
btained before the onset of conditioning, before
ransplantation, and 1 week after transplantation.
ATERIALS AND METHODS
nclusion Criteria
A diagnosis and disease status appropriate for allo-
CT but considered to be ineligible for a standard con-
itioning regimen were required. For patients50 years
f age, additional high-risk criteria were required, eg,
erious comorbid medical conditions, an Eastern Coop-
rative Oncology Group performance status of 2, ad-
anced disease status, or a previous transplantation.
linical Characteristics
The median age of the 26 patients was 49.8 years
range, 22-72 years); 15 were50 years old, and 1 was
2 years old. Clinical diagnoses are listed in Table 1.
ll but 1 patient had previously undergone extensive
hemotherapy. Two patients were in ﬁrst remission,
nd 2 were in second remission. All others were in
elapse or had an advanced disease status. Five patients
ad undergone prior transplantations; 3 had received
utologous transplants for Hodgkin lymphoma and
ultiple myeloma, and 2 had undergone prior allo-
CT for acute myelogenous leukemia (AML). l
B&MTonor Criteria
Donors were required to be hematologically nor-
al HLA-identical siblings without contraindications
or granulocyte colony-stimulating factor (G-CSF) or
nesthesia. There were no age limitations.
onditioning and GVHD Prophylaxis Regimens
Four patients were conditioned with busulfan 4
g/kg intravenously in divided doses from day 7 to
ay 4 (total dose, 16 mg/kg), and the remaining
atients were conditioned with intravenous melphalan
dministered on day5. All drug doses were based on
he lesser of actual or corrected ideal body weight.
uring the study period, the dose of melphalan was
ecreased from an original dose of 240 to 220 mg/m2
nd ﬁnally to 200 mg/m2 intravenously to reduce
oxicity. The monoclonal antibody T10B9 (clone
EDI-500; MedImmune Corp., Gaithersburg, MD)
as administered as a single intravenous injection of
2 mg/d from day 3 to day 7. Although T10B9
ad been given as a 14-mg twice-daily dosage in ear-
able 1. Clinical Characteristics
Variable Data Disease Status
o. patients 26
ge, y, median (range) 50 (22-72)
ex (M/F) 19/7
iagnosis
Non-Hodgkin
lymphoma
9 ADS  8, age  4,
PS  2, PIF  6
Acute myeloid
leukemia
8 Relapse  3, ADS 
4, age  5, second
SCT  2
Acute lymphoid
leukemia
4 Relapse  1, ADS 
2, PS  2
Chronic myelogenous
leukemia
(accelerated
phase)
2 ADS  2, age  1,
second SCT  1
Hodgkin lymphoma 1 ADS, PS, second SCT
Myelodysplastic
syndrome
1 ADS, refractory
anemia
Multiple myeloma 1 ADS, second SCT
ligibility criteria (no. of
patients with
each)
Age >50 y 15
Comorbid disease 3
Morbid obesity 1
Renal failure 1
Cardiomyopathy 1
Advanced disease
status
19
Prior SCT (allogeneic
and autologous)
5
Autologous 2
Allogeneic 3
DS indicates advanced disease status; PIF, primary failure of
induction; PS, decreased performance status; SCT, stem cell
transplantation.ier clinical kidney and cardiac transplantation studies,
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8harmacokinetics and a pilot study in kidney/pancre-
tic transplantation suggested that 42 mg would en-
ure an excess of T10B9 throughout the 24-hour pe-
iod (unpublished data). Cyclosporine 3.0 mg/kg
ntravenously was started on day 5 and was sched-
led to continue by mouth until day 180 with target
lood levels of 250 pg/L.
tem Cell Source
Initially, bone marrow was used in 13 patients.
ne of these 13 bone marrow recipients received
-CSF–mobilized marrow [25]. Later in this study,
3 patients received G-CSF–mobilized peripheral
lood stem cells. The mean number of CD34
ells infused was 5.68  6.65  106, and the median
as 4.3  106. One patient with chronic myelogenous
eukemia in blast crisis received 36.23  106 CD34
ells, but this resulted in no signiﬁcant difference in
he day of absolute neutrophil count 500/L or
latelet independence. This patient did not develop
VHD and survived for 423 days.
onor Leukocyte Infusion
Donor leukocyte infusion was optional for patients
ho did not achieve complete remission and did not
ave grade II or greater aGVHD or extensive chronic
VHD (cGVHD). When administered, the initial
ose was 1  107/kg CD3 cells. If no GVHD oc-
urred within 2 more months, patients were eligible
or a second dose of 5  107cells per kilogram. Only
patients in this series received donor leukocyte in-
usions.
upportive Care
Allopurinol, intravenous ﬂuids, empiric antibiot-
cs, and prophylactic and/or empiric antifungal drugs
ere used routinely. Acyclovir was given prophylacti-
ally to herpes simplex virus–seropositive patients
rom day 1 to day 30 or longer if they required
teroids or if GVHD was present. Ganciclovir was
iven empirically to cytomegalovirus (CMV)–sero-
ositive patients. Total parenteral nutrition was not
outinely used.
erum Cytokine Assays
Peripheral blood was obtained by venipuncture for
ytokine analysis for 21 of the 26 patients. Samples
ere drawn before the onset of conditioning, on pre-
ransplantation days 1 or 0, and 6 to 8 days after
ransplantation. Serum was separated and stored at
70°C. All samples were analyzed simultaneously.
ytokine assays for TNF- and IL-6 were performed
y enzyme-linked immunosorbent assay (R&D Sys-
ems, Minneapolis, MN) by following the manufac-
urer’s instructions. All samples were tested in dupli-
ate or triplicate and compared with a standard curve, I
60nd the results were expressed as the average of the
eplicates.
eripheral Blood Immunophenotyping
To determine the effect of the conditioning regi-
en, aliquots of the same blood samples were ob-
ained for leukocyte phenotyping. Using speciﬁc phe-
otyping antibodies, absolute CD3, CD4, CD8,
D20, and CD56/16 counts were determined by ﬂow
ytometry at the indicated times. The mean of sam-
les obtained before conditioning was compared with
he means of the samples obtained before and after
ransplantation.
tatistical Analysis
The absolute numbers of CD3, CD4, and
D8 cells were compared by using an analysis of
ariance for a repeated-measures design with post hoc
omparison of means depending on the Fisher pro-
ected least signiﬁcant differences procedure.
To determine the effect of the conditioning regi-
en on inﬂammatory cytokines, 3 time periods were
onsidered: period 1, baseline (before conditioning);
eriod 2, before transplantation (days 1 or 0), and
eriod 3, after transplantation (days 6 to 8). A
inear mixed model was used to compare mean re-
ponse across periods for each cytokine value. Because
ot all patients had measurements in all 3 periods, the
ataset was unbalanced. Post hoc comparison of
eans was based on the least-squares means to ac-
ount for missing responses that were assumed to have
ccurred at random. Satterwhaite’s approximation was
sed to estimate the degrees of freedom associated
ith the t tests based on these least-squares means.
tatistical signiﬁcance was determined at the .05 level
hroughout all analyses.
ESULTS
arly Deaths
Two patients died of infectious complications on
ays 3 and 8 (Table 2).
ngraftment
The remaining 24 patients engrafted with an abso-
ute neutrophil count 500/L on median day 10
range, day 8-14) and with platelet recovery20 000/L
n median day14 (range, day 7-100). The median day
f the last erythrocyte transfusion was day 23 (range,
ay 7-60). Chimerism determined by variable number of
andem repeats analysis demonstrated 95% donor he-
atopoiesis in 17 of 19 patients and partial chimerism in
others by day 30. One of the partial-chimerism
atients later converted spontaneously to full chimerism.
n the other, residual and progressive malignant disease
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T Cell–Specific Monoclonal Antibody in Novel Allo-SCT
Bomplicated the assessment of chimerism analysis. Two
ther patients, assayed only on day 100, were fully
himeric. One patient became aplastic during treatment
or human herpes virus-6 with acyclovir and foscarnet
ut underwent successful retransplantation from his
riginal donor and remained disease free at day 1418.
raft-versus-Host Disease
All 24 patients who engrafted were evaluable for
VHD. Of these, 11 (46%) had grade 0 or I, 6 (25%)
ad grade II, and 7 (29%) had grade III or IV
GVHD. Four deaths in the group with grade III or
V disease were directly attributable to aGVHD. This
ncluded 2 of 4 patients who received busulfan and 2
f 16 patients at risk who received melphalan 200
g/m2. One of 2 patients who received melphalan 240
g/m2 developed grade II aGVHD and recovered but
ied of recurrence on day 457. Of the others, 1 had
rade III aGVHD but died of infection, 2 died much
ater of infection, and 1 survived. Only 3 of 16 patients
ho survived 100 days developed cGVHD: 1 with
rade I skin disease, 1 with grade II skin disease, and
with grade III skin disease. Of note, another 7 of the
6 experienced grades I to III aGVHD but did not
evelop cGVHD. Although 2 of the 5 long-term sur-
ivors developed and recovered from aGVHD, none
able 2. Outcomes
Variable
Co
Busulfan
4 mg/kg/d  4 240 m
otal no. Patients 4 3
NC >500/L* 12 (8-14) 9 (8-1
latelets >20 000/L* 14 (9-20) 30 (11
ast RBC* 21 (0-54) 18 (12
GVHD
No. at risk† 4 2
Grade 0-I 1 1
Grade II-IV 3 1
Grade III-IV/deaths 2/2 0
auses of death
No. at risk‡ 4 3
Sepsis infection 0 2
aGVHD† 2 0
Relapse progressive
disease 1 1
RRT§ 0 0
Other 0 0
ollow-up (914-1532 d)
Survival 1 0
DFS 1 0
BC indicates red blood cells.
Engraftment: mean (range) days after transplantation.
Excludes patients dying on days 3 and 8.
Includes all patients who underwent transplantation.
Regimen-related toxicity.
Disease-free survival.rogressed to cGVHD. b
B&MTegimen-Related Toxicity
Veno-occlusive disease did not occur in any of the
atients, but 8 developed mucositis. Although the num-
ers are small, the incidence tended to correlate with a
ore toxic chemotherapeutic regimen, including 4 of 4
atients who received busulfan and 2 of 3 who received
elphalan 240 mg/m2, 1 of 2 who received melphalan
20 mg/m2, and only 1 in 17 who received melphalan
00 mg/m2. One patient, who received melphalan 220
g/m2, died on day 31 with diffuse alveolar damage.
hese toxic manifestations were one of the factors that
ed to the reduction in melphalan dosage.
nfections
Two patients died early: 1 with an unidentiﬁed
eptic syndrome on day 3 and another with Staphylo-
occus aureus and Candida albicans bacteremia on day 8.
hree patients (13%) developed adenovirus infection,
nd 1 died of disseminated infection on day 72. One
atient developed disseminated varicella-zoster virus
ithin the ﬁrst 30 days but recovered. CMV was
ultured from the nasopharynx in 3 patients and from
he bowel in 3 patients. Four of the 6 were asymp-
omatic, but 2 patients (8%) developed CMV colitis
ithin the ﬁrst 100 days. In both, the colitis resolved,
ing Drug
Total Incidence
Melphalan
220 mg/m2 200 mg/m2
2 17 26
11 (10-12) 10 (8-13) 10 (8-14)
63 (27-100) 17 (7-38) 14 (7-100)
61 (21-100) 18 (0-60) 23 (0-100)
2 16 24
2 7 11 (45%)
0 9 13 (55%)
0 5/2 7/4 (29%/17%)
2 17 26
0 5 7 (23%)
0 2 4 (17%)
1 3 6 (23%)
1 0 1 (4%)
0 3 3 (12%)
0 4 5 (19%)
0 4 5 (19%)ndition
g/m2
0)
-48)
-23)ut 1 patient died of recurrent AML on day457; the
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8ther died on day 700 with complications of pulmo-
ary, cardiac, and seizure disorders.
urvival (Follow-up 914-1532 Days)
Twenty patients (77%) survived to day 50, and
6 (62%) survived to day 100 (Figure 1). Three of
he 6 deaths in the early (50 days) period were
ttributed to infections on days 3, 8, and 50; 1
as due to aGVHD on day 43; 1 patient had
GVHD but died of fungal and bacterial infection on
ay 47; and the sixth died of diffuse alveolar damage
RRT) on day 31. An additional 4 patients died by
ay 100 because of progressive disease (day 51),
ecurrence (day 100), disseminated adenovirus in-
ection (day 72), and grade IV aGVHD (day 56).
f the 16 patients who survived for 100 days, 1
ML patient developed extramedullary relapse ap-
roximately 1 year after transplantation and died on
ay 428. Another 3 patients died of recurrence on
ays 423, 457, and 611. One of these developed
rade III aGVHD after discontinuation of GVHD
rophylaxis but succumbed to recurrent disease.
omplete remission persisted until death in 7 more
atients, who died of the following causes: aGVHD
n day 103, infection on day 134, renal failure
n day 196, sepsis and systemic fungal disease on
ay 352, acute respiratory distress syndrome and
enal failure on day 423, heart failure on day 426,
nd disseminated herpes zoster on day 700. Five
atients (19%) were disease free beyond 914 days: 1
atient with myelodysplastic syndrome, indeterminate
tage (aged 53 years); 1 patient with AML in second
omplete remission (aged 72 years); 1 patient with
ML in ﬁrst relapse (aged 55 years); and 2 patients
ith non-Hodgkin lymphoma in advanced disease
tage after primary induction failure (aged 44 and 51
igure 1. Patient survival: Kaplan-Meier plot of survival of 26
igh-risk patients receiving single-agent chemotherapy plus T10B9
nti–T cell conditioning.ears). One received busulfan induction and a bone C
62arrow graft, and 4 received melphalan (200 mg/kg)
nduction followed by primed peripheral blood stem
ells.
aboratory Results
To test the effect of a single daily infusion of 42
g of T10B9 on T lymphocytes, the absolute num-
ers of cells expressing CD3, CD4, and CD8 were
etermined in 14 of the 26 patients before the onset of
he infusion and on the day of the last T10B9 infusion.
here was a marked decrease in absolute numbers of
D3 T cells from 1340/L at the onset of treatment
o 5/L at the end of treatment. Figure 2 illustrates
he results in log 10 function. CD4 cells decreased
rom 618 to 32/L, and CD8 cells decreased from 777
o 65/L. Although there was a decrease in CD4 and
D8 T cells at the end of T10B9 treatment, there
ere substantially more T cells bearing these surface
arkers than could be accounted for by the number of
D3 cells. Comparison of mean CD3, CD4, and
D8 values on the last day of T10B9 treatment (after
og transformation) showed that geometric means var-
ed signiﬁcantly by type of count (F2,22 	 7.40; P 	
0035). Post hoc analysis demonstrated that the geo-
etric mean for CD3 cells was signiﬁcantly smaller
han the corresponding means for the CD4 (P 	
004) and CD8 (P	 .002) cells but that the CD4 and
D8 counts were not different (P 	 .78). Thus,
10B9 induces modulation of the surface expression
f CD3, but not CD4 or CD8, molecules during
dministration to bone marrow transplant recipients
s it does in recipients of solid organs.
Previous in vivo studies have demonstrated that
10B9 does not cause a major increase in serum
NF- and IL-6 when used to treat transplantation
ejection or to prevent rejection in cardiac transplan-
igure 2. Effect of MEDI-500 on absolute CD3, CD4, and
D8 peripheral blood T-cell counts (log 10). Data are mean 
EM. Note the number of cells before initiation of MEDI-500 and
t the end of 10 days of treatment. Also note that at the end of
reatment, the CD3 count was signiﬁcantly lower than either the
D4 or CD8 counts.
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Bation. However, we did not know the effect of T10B9
f it was administered after an alkylating agent and
llo-SCT. To address this question, we compared
erum IL-6 and TNF- levels obtained before condi-
ioning (period 1) with those obtained after condition-
ng but before SCT (period 2) and with samples ob-
ained 6 to 8 days after transplantation (period 3).
amples were obtained from 19 patients in each pe-
iod, but only 15 of these had samples for all 3 time
eriods. The mixed linear model showed that both
ytokines had signiﬁcant changes in mean response
ver time (Figure 3). The F statistic for IL-6 compar-
ng the 3 means was 5.70 (2 and 33 df; P 	 .007), and
or TNF- the F statistic was 4.89 (2 and 31 df; P 	
014). The mean TNF- decreased progressively be-
ween periods 1, 2, and 3 (14.6  3.2 pg/mL, 10.3 
.2 pg/mL, and 6.4  3.3 pg/mL, respectively), and
ean IL-6 increased progressively (42.6  33.1 pg/
L, 64.8  33.0 pg/mL, and 121.4  33.7 pg/mL,
espectively). Posttransplantation (period 3) levels of
NF- were statistically different from (lower than)
heir period 1 preconditioning levels (P 	 .004), and
L-6 levels in period 3 were different from (higher
han) both their period 1 preconditioning (P 	 .002)
nd period 2 pretransplantation levels (P 	 .025).
ISCUSSION
In recent years, a number of alternative regimens
igure 3. TNF- (a) and IL-6 (b) serum levels obtained before
onditioning, before transplantation, and 6 to 8 days after trans-
lantation. Data are mean SEM. Note the progressive decrease in
NF- and the increase in IL-6 levels over the 3 periods.ave been explored to reduce or eliminate the myeloa- o
B&MTlative agents used in conventional protocols and, by so
oing, to include patients who ordinarily cannot un-
ergo transplantation because of age, disease status, prior
ransplantation, or comorbid conditions [20,26-28]. Al-
hough many different regimens have been designed to
educe myeloablation, common elements have included
ombinations of the following for immunosuppression:
udarabine [16,21], low-dose TBI [20,22,27], antithy-
ocyte globulin [16,17,28,29], and alemtuzumab (Cam-
ath-1H; Berlex Laboratories, Seattle, WA) [30-32]. In
ddition to the added immunosuppressive effects of ﬂu-
arabine and TBI, cyclophosphamide [29,33], busulfan
16], melphalan [21,30], and other drugs have been
dded for their speciﬁc antineoplastic properties. In
ome regimens, mycophenolate mofetil has been added
o conventional cyclosporine [22,27] for post-
ransplantationGVHDcontrol and to help with engraft-
ent [27].
The central theme behind all of the reduced my-
loablative regimens is the concept that immunosup-
ression of host T cells, rather than making space by
yeloablation, is the critical requirement for success-
ul engraftment of allo-SCT [26-32,34,35]. Several
ears ago, we developed a powerful anti–T cell mono-
lonal antibody, T10B9. Basic and preclinical studies
24,25,36] demonstrated that T10B9 is an immuno-
lobulin M 
 protein that speciﬁcally targets cells
xpressing the  chains of the T-cell receptor and
pares cells expressing the  T-cell receptor [25,37].
he result is modulation of the receptor of the surface
f the targeted T cells and apoptosis. An important
haracteristic of T10B9 is that it is not mitogenic and
as a reduced capacity to stimulate the production of
nﬂammatory cytokines [24,25]. Another potential ad-
antage for T10B9, as a conditioning agent, is its short
alf-life of24 hours. Therefore, T-cell immunosup-
ression can be localized to a speciﬁc period without
he disadvantage of prolonged suppression.
T10B9 has been extensively used for ex vivo T-cell
epletion [38,39] and as one of the T-cell depletion
rms in the National Heart, Lung, and Blood Insti-
ute–sponsored multicenter unrelated bone marrow
ransplant study [40]. In vivo, T10B9 has also been
ound to very successfully treat kidney allograft rejec-
ion [41] and prevent solid-organ rejection [42] and to
o so with minimal toxicity. It targets the / chains
f the T-cell receptor and induces modulation of the
-cell receptor of the cell surface and apoptosis. The
nfusion results in a dramatic decrease in circulating
D3 T cells within 10 to 30 minutes after infusion.
fter 3 to 5 days of daily infusion with T10B9, new
D4 and CD8 T cells begin to reappear in the
irculation, but they continue to express low levels of
D3 on their surface by ﬂow cytometry as long as the
ntibody is continued [24,25]. Within 48 hours after
essation of treatment, CD3 reappears on the surface
f circulating lymphocytes. On the basis of this exten-
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8ive background, T10B9 was considered an attractive
gent for the immunosuppression component of con-
itioning in a single-agent allo-SCT trial. However,
his raised the question of whether T10B9 would have
he same effect on circulating lymphocytes and cyto-
ines in this protocol as compared with that reported
n solid-organ transplantation. The data demonstrate
uite clearly that T10B9 induced modulation of sur-
ace CD3 in patients undergoing allo-SCT similar to
hat previously observed in solid-organ transplanta-
ion.
We continued treatment with T10B9 for 6 to 7 days
fter transplantation for 2 reasons. The ﬁrst was simply
o delay the necessity for cyclosporine and thereby re-
uce the incidence and severity of nephrotoxicity and
eurotoxicity in this early post–allo-SCT period. The
econd was based on experimental evidence that estab-
ished that host T cells were the predominant source of
NF- during the ﬁrst 3 to 5 days in a murine models
f allogeneic bone marrow transplantation [43,44]. We
elieve that this accounts for the observed progressive
ecrease in TNF- levels from the preconditioning sam-
les to the pretransplantation samples taken after 3 days
f T10B9 and to the samples obtained at the end of
10B9 therapy on day 6 to 8 after transplantation. In
ontrast, note that IL-6, which is not produced by T
ells, increased progressively over these time periods.
Our initial choice for an antineoplastic agent during
onditioning was too toxic. Two of the 4 patients treated
ith busulfan (4 mg/kg/d 4 days for a total dose of 16
g/kg; Table 2) died of aGVHD on days43 and56.
nother died of disease recurrence in the presence of
rade II aGVHD. The fourth was alive at 1246 days.
ll 4 developed stomatitis. Because of a protocol exclu-
ion for prior use and these results with busulfan, we
sed the protocol-speciﬁed alternative, ie, a single dose
f melphalan, as the study progressed. However, we
ound that the initial choice of melphalan doses of 220 to
40 mg/m2 were too toxic in these patients. Two of the
who received 240 mg/m2 died with sepsis on day 8 and
0, and 1 of 2 who received 220 mg/m2 died of diffuse
lveolar damage and infection on day 31. Three of 5
atients who received 240 or 220 mg/m2 developed
tomatitis. Therefore, the dose of melphalan was re-
uced to 200 mg/m2 administered on day5. Of the 17
atients treated with this dosage of melphalan, 4 were
live and disease free at follow-up at 914 -1, 532 days.
Several important points distinguish the results of
his trial from those of other published reports. (1) Fail-
re to engraft and graft failure have been signiﬁcantly
ncreased with some of the reduced myeloablative pro-
ocols [19,22,27,29]. All evaluable patients in this study
ngrafted promptly. Three patients never required red
lood cell support. Furthermore, 95% donor chimer-
sm was demonstrated in all but 1 of 21 patients in whom
t was tested. We believe that this strongly supports the
onclusion that the daily injection of T10B9 provided
64dequate host immunosuppression. (2) In some other
rotocols, a high incidence of infection has been re-
orted. In our study, CMV was cultured in 6 (23.1%) of
6 patients. Four were asymptomatic, and only 2 patients
8%) developed CMV colitis. This is contrast to the
igher incidence of CMV reactivation in 46.6% of pa-
ients treated with Campath-1H for aGVHD prophy-
axis [31,32]. The difference in the CMV infection rate
ay relate to the more prolonged immunosuppression
hat results from humanized Campath-1H or to its effect
n non–T cells and T cells. (3) The incidence of
GVHDwas higher in our patients than in those treated
ith Campath-1H [30,35] but was generally comparable
ith the overall incidence when mycophenolate/cyclo-
porine [22,27] or cyclosporine/prednisone [16,21] was
sed for GVHD prophylaxis. Although mycophenolate
elayed the onset, aGVHD often occurred after drug
essation.
We [13,14] have demonstrated increased levels of
erum TNF-, IL-1, and IL-6 in mice after TBI,
hereas there was much less of an increase after either
usulfan or cyclophosphamide conditioning. Therefore,
e reasoned that deletion of a myeloablative dose of TBI
rom the conditioning regimen might reduce the induc-
ion of high levels of these proinﬂammatory cytokines
nd, correspondingly, reduce the incidence of RRT and
GVHD. Our pilot trial does not conﬁrm or refute this
heory because there was no comparable high-risk con-
rol group that received traditional conditioning with
BI. Taken in the context that all of the patients entered
n this trial were considered to be at too high a risk for a
raditional allo-SCT, the fact that 5 of 26 patients are
njoying long-term disease-free survival is encouraging.
owever, 2 patients died of sepsis within 8 days of
ransplantation. The ability to select more favorable pa-
ients from the high-risk pool could be an important
actor, not only for entry into this protocol, but also
erhaps as a general guide for patients being considered
or other reduced-myeloablative-conditioning protocols.
In conclusion, the use of the T cell–speciﬁc mono-
lonal antibody T10B9 in a conditioning regimen with
ingle-agent chemotherapy achieved durable engraft-
ent and long-term survival in high-risk patients who
ould not have qualiﬁed for a conventional SCT.
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